Kite Pharma, Inc.
KITE
KITE was delisted on the 2nd of October, 2017.
173 hedge funds and large institutions have $1.88B invested in Kite Pharma, Inc. in 2016 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 75 increasing their positions, 41 reducing their positions, and 24 closing their positions.
154% more call options, than puts
Call options by funds: $32.3M | Put options by funds: $12.7M
83% more repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 41
17% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 24
12% more capital invested
Capital invested by funds: $1.69B → $1.88B (+$199M)
1% more funds holding
Funds holding: 171 → 173 (+2)
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
+$23.7M |
| 2 |
JP Morgan Chase
New York
|
+$18.7M |
| 3 |
Viking Global Investors
Stamford,
Connecticut
|
+$13.1M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$11M |
| 5 |
MMH
Menora Mivtachim Holdings
Ramat Gan,
Israel
|
+$9.33M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$27.6M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$19.4M |
| 3 |
JMPWA
JP Morgan Private Wealth Advisors
San Francisco,
California
|
-$18.3M |
| 4 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
-$11.3M |
| 5 |
VC
Vivo Capital
Palo Alto,
California
|
-$8.87M |
KITE Hedge Fund Activity: Q2 2016 in Review
173 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Kite Pharma, Inc. (KITE) for Q2 2016, worth a combined $1.88B — up 12% from $1.69B a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new KITE positions and 24 closed out — a net gain of 4 holders — while 75 added to existing stakes and 41 trimmed.
The largest buyer was Capital World Investors, adding an estimated $23.7M. The largest seller was Citadel Advisors, cutting an estimated $27.6M.
- 173 institutional investors held Kite Pharma, Inc. (KITE) as of Q2 2016, up from 171 in Q1 2016.
- Funds reported $1.88B of Kite Pharma, Inc. stock for Q2 2016, up 12% quarter-over-quarter.
- 28 funds opened new Kite Pharma, Inc. positions in Q2 2016 and 24 closed out, a net change of +4 holders.
- The largest Kite Pharma, Inc. buyer in Q2 2016 was Capital World Investors, an estimated $23.7M added.
- The largest Kite Pharma, Inc. seller in Q2 2016 was Citadel Advisors, an estimated $27.6M sold.
Based on aggregated 13F filings for Q2 2016.